Vigil Neuroscience, Inc.

VIGL

US92673K1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
4.03 ^USD	+2.03%		+0.75%	+19.23%

01/07	Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 3000E Value Index	CI
01/07	Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Value Index	CI

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 3000E Index

July 01, 2024

Latest news about Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 3000E Value Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Value Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2500 Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 3000 Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 3000 Value Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2500 Value Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Dynamic Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell Small Cap Comp Value Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell Small Cap Completeness Index	01/07	CI
Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 3000E Index	01/07	CI
Wedbush Adjusts Price Target on Vigil Neuroscience to $23 From $22 on Heels of Sanofi Investment, Maintains Outperform Rating	28/06	MT
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	27/06	MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data	27/06	MT
Top Premarket Gainers	27/06	MT
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment	27/06	DJ
Vigil Neuroscience Receives $40 Million Investment From Sanofi	27/06	MT
Vigil Neuroscience, Inc. announced that it has received $3.999997 million in funding from Sanofi Pasteur Biologics, LLC	27/06	CI
Transcript : Vigil Neuroscience, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:40 AM	11/06
Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	18/04	CI
Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating	26/03	MT
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ

Chart Vigil Neuroscience, Inc.

Duration

Period

More charts

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimerâs disease in genetically defined subpopulations.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.03 USD

Average target price

16.88 USD

Spread / Average Target

+318.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIGIL NEUROSCIENCE, INC.	+19.23%	151M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research